Key takeaways

  • Human review must be effective, not ceremonial
  • Consequences should determine oversight level
  • Show the basis and known/unknown inputs
  • Monitor overrides, escalation and drift after launch

The short version

Start by defining which decisions are automated, which require review, what evidence the clinician sees, how they override the model and how the system records that decision. The practical question is not whether the concept can be reduced to a single score or rule, but whether the information is specific enough to support the next clinical or family decision. Articu’s editorial position is to preserve context, target, language, practice level, cueing, recording quality and uncertainty, rather than present false precision.

Human review must be effective, not ceremonial

Human review must be effective, not ceremonial. In real speech practice, this distinction matters because the same surface result can come from different causes and can require different responses. A useful record therefore keeps the observation close to its context instead of converting it immediately into a diagnosis or universal recommendation.

NIST, AI Risk Management Framework 1.0 is useful context here. NIST organizes AI risk management around Govern, Map, Measure and Manage, including documented human oversight, evaluation under deployment-like conditions and ongoing monitoring. The lesson is not that every product or clinic must copy one study protocol; it is that claims should stay within the population, language, task and evidence that were actually evaluated.

Consequences should determine oversight level

Consequences should determine oversight level. In real speech practice, this distinction matters because the same surface result can come from different causes and can require different responses. A useful record therefore keeps the observation close to its context instead of converting it immediately into a diagnosis or universal recommendation.

NIST, Generative AI Profile for the AI RMF is useful context here. The NIST GenAI Profile extends risk-management guidance to generative systems, emphasizing inventories, evaluation, human-AI configuration, data provenance, incident response and ongoing review. The lesson is not that every product or clinic must copy one study protocol; it is that claims should stay within the population, language, task and evidence that were actually evaluated.

Show the basis and known/unknown inputs

Show the basis and known/unknown inputs. In real speech practice, this distinction matters because the same surface result can come from different causes and can require different responses. A useful record therefore keeps the observation close to its context instead of converting it immediately into a diagnosis or universal recommendation.

FDA, Clinical Decision Support Software Guidance is useful context here. FDA guidance emphasizes that clinicians should be able to independently review the basis for recommendations, understand known/unknown inputs and apply their own judgment; it also discusses automation bias. The lesson is not that every product or clinic must copy one study protocol; it is that claims should stay within the population, language, task and evidence that were actually evaluated.

What this means in practice

  • Define the workflow and decision owner before selecting the AI feature.
  • Measure review burden, override rate and failure modes, not just adoption.
  • Make source evidence and uncertainty available at the point of review.
  • Write down retention, training-use, vendor-update and stop/rollback rules before the pilot expands.

What technology can help with, and where it stops

A dashboard or model can reduce clerical friction only when it is embedded in a workflow with clear ownership. Automation should not convert missing context into confident documentation, and “human in the loop” should mean the reviewer has enough time and evidence to disagree. For higher-consequence uses, local validation, monitoring and a stop path matter as much as initial vendor accuracy.

Questions to ask before acting on the output

Ask what population and task the system was validated on, what the model does when it is uncertain, which version produced the result, whether a clinician can inspect the supporting evidence, and how corrections are recorded. For any feature that can influence documentation or clinical decisions, the workflow should make disagreement easy and preserve a human-owned final decision.

The Articu perspective

Articu’s workflow goal is selective review: summarize routine practice, route uncertainty to a clinician, preserve the supporting recording where policy allows, and keep model output separate from clinician-confirmed data.

Sources and further reading

Editorial status: Draft prepared from current literature and authoritative guidance; clinical reviewer pending.

Educational disclaimer: This article is general educational information, not an assessment, diagnosis, or individualized treatment plan. Speech development varies by age, language, dialect, hearing, motor and developmental context. For individual concerns, consult a qualified speech-language pathologist.